98%
921
2 minutes
20
Background: Despite being curable, tuberculosis is still a stigmatized disease. Not only is TB patients' suffering due to its clinical manifestations, but also because of society's prejudice, embarrassing situations, and even self-discrimination. This study aims to investigate psychosocial experiences of patients who have completed tuberculosis treatment in São Carlos a municipality in the interior of São Paulo State, Brazil.
Methods: This study, of a clinical-qualitative nature, sought to understand the meanings provided by the participants themselves. Fifteen individuals, who had successfully completed tuberculosis treatment, participated in this research. The sample size was established using the information saturation criterion. Data were collected by means of interviews with in-depth open-ended questions. Data were treated by categorizing and analyzing content according to themes.
Results: Regardless of all progress, this study found that TB still causes patients to suffer from fear of transmission, social prejudice, and death. Despite the fact that the emotional support provided by families and healthcare professionals is considered essential to treatment adherence and completion, participants in this study reveal that friends and colleagues have distanced themselves from them for fear of contagion and/or prejudice. Ignorance about the disease and its transmission modes can be found in the interviewees' statements, which seems to indicate that they have become vectors of transmission of stigma themselves. Patients' medical leave from work during treatment may be due to both their health conditions and their attempt to avoid social/emotional embarrassment. There are accounts that TB has caused psychosocial damage to patients' lives and that they feel more fatigue and lassitude and have begun to pay more attention to their own health.
Conclusions: Healthcare workers should be aware of the ways TB treatment affect patients' psychosocial life and develop strategies to mitigate these effects and provide opportunities for them to share their anxiety, suffering, and bio-psychosocial changes. In addition, healthcare professionals should seek to educate and, as a result, empower TB patients and their families with regard to this disease so as to break the existing vicious cycle of misinformation and prejudice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691587 | PMC |
http://dx.doi.org/10.1186/1471-2458-13-595 | DOI Listing |
Clin Infect Dis
September 2025
Tuberculosis Unit, Department of Infectious Diseases, Bellvitge University Hospital-Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Background: This study builds on previous evidence to assess the risk of tuberculosis (TB) in patients treated with biologic therapies (BioT), the role of the interferon-γ-release assay (IGRA) QuantiFERON-TB (QFT) Gold as a stand-alone screening test, and whether periodic re-testing is warranted for patients with a negative pre-BioT screening.
Methods: A total of 1,368 patients starting BioT were screened for TB infection using four screening strategies over four consecutive periods: (1) two-step tuberculin skin test (TST); (2) two-step TST plus QFT Gold In-Tube; (3) single-step TST plus QFT Gold In-Tube; and (4) QFT Gold In-Tube (or QFT Gold Plus) alone. All patients with TB infection were offered preventive therapy.
Cureus
August 2025
Family Medicine, Chino Valley Medical Center, Chino, USA.
This case presents a 25-year-old Indian male with no significant past medical history presenting to the emergency department (ED) due to two weeks of productive cough with pleuritic chest pain. The patient presented one week earlier to the ED; however, he left against medical advice and was given a 5-day course of Azithromycin 250 mg that minimally improved his symptoms. He returned to the ED shortly after completing the antibiotics and was admitted for further evaluation.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461.
The ESX-5 secretion system, uniquely found in slow-growing mycobacteria, is predicted to secrete over 150 proteins across the inner membrane of (). Although many of these substrates are believed to promote virulence, most remain poorly characterized. Here, we use a complete locus deletion strain of ESX-5 in to examine the molecular changes caused by a broad loss in ESX-5 secretory substrates.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
Department of Tuberculosis, The Fourth People's Hospital of Nanning, Nanning, 530023, Guangxi, China.
Tuberculosis (TB) remains a significant global public health challenge, despite recent advances in drug development. However, a comprehensive and systematic overview of the current clinical trial landscape in TB prevention and treatment is still lacking. This study aims to systematically review recent breakthroughs in TB drug development, assess their scientific value and global impact, and provide valuable insights for clinicians and policymakers involved in TB control efforts.
View Article and Find Full Text PDFJ Clin Microbiol
September 2025
The Johns Hopkins Medical SystemsBaltimore, Maryland, USA.
Rapid diagnosis of resistance-conferring mutations to antibiotics used for the treatment of tuberculosis (TB) is critical for patient care and public health control efforts. Prior guidelines included the use of fluoroquinolones (FQs) for the treatment of drug-resistant TB, including multidrug-resistant TB, pre-extensively drug-resistant TB, and extensively drug-resistant TB. More recently, a short-course regimen for antibiotic-susceptible TB was introduced, which includes the use of a FQ, a drug class that diagnostic algorithms in the United States (US) typically do not test for if all first-line agents are susceptible.
View Article and Find Full Text PDF